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Background: Differential gene expression offers an attractive means by which to study genes that may be in-
volved in disease development and/or progression. We performed quantitative gene expression in various stages
of esophageal adenocarcinoma, treated exclusively by surgery with complete 2-field lymphadenectomy, in an
attempt to discern genes involved in disease progression as well as genes that may predict survival.
Methods: Gene expression profiling was accomplished by cDNA-mediated annealing, selection, extension, and
ligation (DASL) assay. RNA was extracted from 89 archived formalin-fixed, paraffin-embedded esophageal ad-
enocarcinoma tissues. DASL assay was performed with the Sentrix Universal Array (Illumina Corp, San Diego,
Calif) of 502 known cancer-related genes. Bioinformatics tools were used to determine significant differential
gene expression in T1-2 versus T3-4 tumors and tumors without lymph node involvement (N0) versus tumors
with lymph node involvement (Nþ). Gene expression was also correlated with overall survival.
Results: Twenty-one genes were overexpressed in T1-2 compared with T3-4 tumors (false discovery rate of 0).
Underexpression of 1 gene was seen in Nþ compared with N0 tumors (false discovery rate of 0). For overall
survival, underexpression of 9 genes correlated with long survival.
Conclusions: Using differential gene expression of 502 known cancer genes, we identified genes that may be
involved at various stages in the progression of esophageal adenocarcinoma. We also identified genes that
may correlate with prolonged survival and, thus, may serve as prognostic markers. These findings may provide
further insight into the mechanisms of development and/or progression of esophageal adenocarcinoma. Prospec-
tive studies are needed to verify the prognostic value of these genes.
Hammoud et al General Thoracic SurgeryThe incidence of esophageal adenocarcinoma has increased
markedly over the past 30 years. In theWestern world, adeno-
carcinoma is now more common than esophageal squamous
cell carcinoma.1 Surgical resection, with or without the addi-
tion of chemotherapy and/or radiation therapy, remains the
cornerstone of therapy for esophageal adenocarcinoma and
represents thebest curative treatment option.However, despite
improvements in preoperative staging and in operative mor-
bidity and mortality, the prognosis of patients with adenocar-
cinoma remains relatively poor. A variety of factors have been
explored to determine the biologic behavior of esophageal
adenocarcinoma. Widely known prognostic factors, such as
stage of tumor and lymph node involvement, are included in
the TNM staging system. In addition, other factors such as
the number of positive lymph nodes, grade of differentiation,
and response to neoadjuvant chemoradiation have been shown
to have additional prognostic value.2,3 The description of mo-
lecular and/or genetic changes involved in carcinogenesis has
led to opportunities to explore the impact of such changes on
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may identify additional factors that have the potential to im-
prove prognostication and to influence additional therapy.
Carcinogenesis is a complex process that involves multi-
ple genetic alterations. Many methods have been developed
to study these changes and to delineate their potential impact
on clinical behavior. The sequentiation of the human ge-
nome, combined with high throughput technologies, has
led to the ability to describe these genetic alterations in
a quantitative manner, thus allowing the development of
tumor ‘‘profiles’’ that can distinguish subsets of disease,
predict response to therapy, and possibly outcome. In esoph-
ageal adenocarcinoma, gene expression profiling usingDNA
microarrays has been used to compare adenocarcinoma with
squamous cell carcinoma and with Barrett esophagus, estab-
lishing the presence of unique gene expression profiles capa-
ble of discriminating between these diseases.4
We performed gene expression profiling on formalin-
fixed, paraffin-embedded (FFPE) esophageal adenocarci-
nomas using the cDNA-mediated annealing, selection,
extension and ligation (DASL) assay. Quantitative gene ex-
pressionwas performed in various stages of adenocarcinoma,
treated exclusively by surgery with complete 2-field lympha-
denectomy, in an attempt to discern genes involved in disease
progression as well as genes that may predict survival.
PATIENTS AND METHODS
Patients and Samples
The study was approved by the Indiana University Institutional Review
Board. From 1990 to 2005, 138 patients with the diagnosis of esophagealardiovascular Surgery c Volume 137, Number 4 829
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DASL ¼ cDNA-mediated annealing, selection,
extension, and ligation
DNA ¼ deoxyribonucleic acid
FFPE ¼ formalin-fixed, paraffin-embedded
RNA ¼ ribonucleic acid
adenocarcinoma, treated exclusively by surgery with complete 2-field lym-
phadenectomy as initial therapy at the Indiana University Medical Center,
were identified from a prospectively maintained database. Representative
hematoxylin and eosin–stained slides from all patients were reviewed by
two pathologists (S.B. and R.S.). A section with a minimum of 1 cm2 tu-
mor-bearing area with at least 70% tumor was the selection criterion for in-
clusion in the study. Forty-one specimens did not fulfill this criterion and
were excluded. Specimens with the minimum 1 cm2 tumor-bearing area
but with adjacent or surrounding stromal/granulation tissue were included;
these specimens were subjected to manual macrodissection with hematox-
ylin and eosin slides used to facilitate macrodissection of the tumor-bearing
area. The corresponding paraffin blocks were obtained from the Indiana
University Department of Pathology. Three 10-mm sections were obtained
from each selected paraffin block (one block per case) on noncharged glass
slides taking due precautions to avoid nucleic acid contamination. Sections
were deparaffinized with CitriSolv cleaning agent (Fisher Scientific Com-
pany, Fair Lawn, NJ) and scraped off from the slide into a microcentrifuge
tube. For sections requiring macrodissection, only the tumor-bearing areas
were scraped off using visual matching with marked hematoxylin and eosin
slides. RNA was extracted from a total of 97 cases using High Pure RNA
Paraffin Kit (Roche Applied Bioscience, Indianapolis, Ind). Eighty-nine
cases fulfilled the RNA requirement of 200 ng/5 mL for the assay and served
as the basis for the study. RNA was pre-qualified using iScript (Bio-Rad
Laboratories Inc, Hercules, Calif) to reverse transcribe and SYBR Green
MasterMix (Applied Biosystems, Foster City, Calif) to perform quantitative
polymerase chain reaction for RPL13a gene. DASL assay was performed
with the Sentrix Universal Array (Illumina Corp., San Diego, Calif) of
502 known cancer genes as per the manufacturer’s instructions.5 Technical
duplicates for four samples were also included in the assay.
Clinical follow-up was obtained from office visits and through telephone
contact. The pathologic TNM stage, date of surgery, date of death where
applicable, and the date of last follow-up were recorded. Specimens were
grouped into T1 and T2 tumors (T1-2) or T3 and T4 tumors (T3-4) to
delineate genes that may be involved in advancing T stage as well as
into tumors without lymph node involvement (N0) or with lymph node in-
volvement (Nþ) to delineate genes that may be involved in lymph node me-
tastasis. On the basis of survival from the date of surgery, Kaplan–Meier
survival curves were calculated. A comparison was made on the basis of
patient overall survival to delineate genes that may confer a survival
advantage.
Statistical Analysis
Gene expression data were normalized at the median level. Hierarchical
clustering and singular value decomposition methods were applied to detect
the outliers for quality control purposes. The gene expression data was then
correlated with T stage (1-2 vs 3-4) and with lymph node status (negative vs
positive) through significant analysis of microarray.6 T stage, lymph node
status, and gene expression were correlated with patient overall survival
through log–rank tests. Patients who died perioperatively as well as patients
who died of noncancer causes were censored in the overall survival analysis.
The false discovery rate,7 an estimate of the proportion of errors committed
by falsely rejecting null hypotheses and widely used in genome wide correl-
ative studies, was calculated for each gene. Top-ranked genes were selected830 The Journal of Thoracic and Cardiovascular Suby a prespecified false discovery rate (q value) of 0.20. Gene set analysis
was performed among the top ranked genes.8
RESULTS
Table 1 lists the TNM pathologic stage of all 89 speci-
mens analyzed. There were 26 T1-2 and 62 T3-4 specimens
whereas there were 23 N0 and 66 Nþ specimens. The
median follow-up was 25 months (range 2–132 months)
and 4 patients were lost to follow-up. The median survival
for the entire group was 2.18 years (Figure 1). Analysis of
T1-2 specimens compared with T3-4 specimens demon-
strated up-regulation (overexpression) of a total of 63 genes,
21 of which had a false discovery rate (q value) of 0. Tables
2A and 2B demonstrate the results of this analysis and the
genes identified. Table 3 demonstrates results of the analysis
of N0 specimens compared with Nþ specimens. A total of
16 genes were overexpressed and 1 gene (MYB) was under-
expressed (down-regulated); only the underexpressed gene
had a false discovery rate of 0. For the survival analysis,
no overexpressed genes correlated with prolonged survival.
However, underexpression of 9 genes correlated with pro-
longed survival (Table 4). Figure 2 demonstrates a typical
survival curve for one of these genes (CSPG2 or chondroitin
sulfate proteoglycan core protein 2); the other 8 genes
demonstrated similar survival curves. Figures 3 and 4
TABLE 1. Pathologic TNM stage of 89 specimens used for analysis
TNM stage No.
T1 N0 10
T1 N1 5
T2 N0 4
T2 N1 7
T3 N0 9
T3 N1 51
T4 N1 2
Tx N1 1
FIGURE 1. Kaplan–Meier survival curve of all 89 patients.rgery c April 2009
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T3-4 tumors and of patients with N0 versus Nþ tumors,
respectively.
DISCUSSION
Gene expression profiling has become a powerful tool for
the discovery of unique patterns that can distinguish a variety
of disease states. In combination with statistical analysis,
DNA microarrays have been used to study various cancers
and to categorize them on a molecular level. The microar-
TABLE 2A. Analysis of T1-2 tumors compared with T3-4 tumors
Gene name Fold change q Value (%)
FGF6 1.21921 1.91959
TSC1 1.20543 1.91959
WNT8B 1.12815 1.91959
CDC25C 1.18296 1.91959
MCF2 1.20778 1.91959
DCC 1.19554 1.91959
MOS 1.19179 1.91959
IL13 1.14319 1.91959
FGF3 1.33406 1.91959
RAD54B 1.13327 1.91959
NRAS 1.10673 1.91959
G22P1 1.17275 1.91959
TDGF1 1.19453 2.63944
IGF1R 1.16352 2.63944
IFNG 1.15091 2.63944
TP73 1.20165 3.24854
IGFBP1 1.13768 3.24854
PGR 1.11939 3.24854
EPHA1 1.1288 4.41953
TGFB1 1.14399 4.41953
CSF3 1.17331 4.41953
BLM 1.1637 4.41953
GML 1.19125 5.03894
MYCL1 1.13767 5.63081
ERCC1 1.15039 5.63081
CUL2 1.09062 5.63081
ERCC2 1.13815 7.22374
TYRO3 1.14349 7.22374
NOTCH4 1.07357 7.22374
RRAS 1.14274 7.22374
NOTCH2 1.09151 7.22374
FER 1.12716 7.22374
DDB2 1.10884 7.22374
MTHFR 1.09651 7.22374
COL4A3 1.10613 7.22374
WNT1 1.08621 7.22374
CDC25A 1.09301 7.22374
TRAF3 1.09166 9.04952
WT1 1.14302 9.04952
RET 1.07779 9.04952
ERCC6 1.13908 9.04952
FLT3 1.1193 9.04952
Overexpression of 42 genes with q value greater than 0.The Journal of Thoracic and Crays have been used to generate expression profiles that
may predict disease prognosis, for example, breast cancer,
as well as to delineate tumor pathway profiles.9 In esopha-
geal cancer, gene expression profiling has been used to
differentiate normal esophagus, Barrett esophagus, and ade-
nocarcinoma.4 Such reports have focused mainly on com-
paring adenocarcinoma with other tissues in an attempt to
TABLE 2B. Results of T1-2 tumors compared with T3-4 tumors
Gene name Fold change
MYCN 1.31278
FGF8 1.20703
CYP1A1 1.23692
ERBB4 1.30322
LTA 1.18221
ABCG2 1.25264
ERTV1 1.22501
TNFSF6 1.17038
NTRK2 1.1634
FGF5 1.18971
CHEK1 1.23283
NAT2 1.17645
PMS1 1.18019
MAS1 1.18816
SIAH1 1.12057
PLG 1.19926
FANCA 1.20802
DKC1 1.16013
ALK 1.23865
MPL 1.19515
RARB 1.22884
Overexpression of 21 genes demonstrated a false discovery rate (q value) of 0.
TABLE 3. Analysis of N0 tumors compared with Nþ tumors
Gene name Fold change q value (%)
Overexpressed
SERPINE1 1.232970722 41.30536677
PTHLH 1.121515751 41.30536677
ETV1 1.163101391 41.30536677
WRN 1.119533194 41.30536677
ABCC2 1.180818778 41.30536677
ERG 1.149993726 41.30536677
MPL 1.147600832 41.30536677
PTCH2 1.174312145 41.30536677
ERBB4 1.185113229 41.30536677
ARHH 1.098985548 41.30536677
WNT10B 1.165125114 41.30536677
VAV1 1.08979885 41.30536677
ICAM1 1.121376886 41.30536677
TNFSF6 1.117215827 41.30536677
IL12A 1.097115543 41.30536677
CSF3 1.160386817 41.30536677
Underexpressed
MYB 0.749712525 0
A total of 16 genes were overexpressed and 1 gene was underexpressed.ardiovascular Surgery c Volume 137, Number 4 831
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nose,’’ adenocarcinoma from other tissue types. Dahlberg
and associates10 used microarray analysis of 12,000 genes
and noted that only a small subset of genes distinguished
adenocarcinoma from normal controls. In this report, the
authors compared 10 esophageal adenocarcinoma samples
with 7 normal mucosa samples and found that 64 genes
(of a total of 12,000) were potentially involved in the transi-
tion from normal epithelium to adenocarcinoma. Although
the genes identified in this report did not correlate with our
results, it is important to note that our study compared tu-
mors with other tumors as opposed to normal tissues and
that different genes may be involved in the transition from
normal to tumor than from tumor to more invasive tumor.
Furthermore, the number of specimens analyzed was rela-
tively small whereas the number of genes analyzed was
very large; thus, statistical analysis of such data may be dif-
ficult to compare with our data. Selaru and colleagues11 also
used cDNAmicroarrays and reported that various gene clus-
ters were able to distinguish Barrett, adenocarcinoma, and
squamous cell carcinoma. This report used a small number
of samples and generated gene ‘‘clusters’’ that correlated
TABLE 4. Underexpressed genes that correlated with prolonged
survival
Gene name q Value (%) P value
CSPG2 7.1 .0001
COL1A1 9.1 .0004
IGFBP3 7.1 .0004
SPP1 9.5 .0007
MMP14 8.3 .0008
CDH11 15.7 .0002
TIMP1 14.1 .0002
TGFB3 18.8 .0003
MYB 19.7 .0004
FIGURE 2. Kaplan–Meier survival curve of patients based on expression
of CSPG2.832 The Journal of Thoracic and Cardiovascular Suwith tissue histologic characteristics. The authors did not
identify specific genes. Greenawalt,4 Hao,12 and their asso-
ciates used genome-wide gene expression profiling to iden-
tify candidate genes that may play a role in esophageal
cancer carcinogenesis. These reports, unlike ours, again fo-
cused on a comparative analysis between Barrett and adeno-
carcinoma. In another report, Kimchi and colleagues13
reported gene expression profiling of Barrett and adenocar-
cinoma and found that 21 genes may represent potential
markers of disease progression; six of these genes showed
significant correlation with progression from normal to Bar-
rett to adenocarcinoma. Common to all of these studies is the
underlying assumption that Barrett esophagus is the genetic
precursor to invasive adenocarcinoma. Guo and coworkers14
reported that distinctive microRNA expression profiles may
relate to patient survival in esophageal squamous cell carci-
noma, whereas Feber and colleagues15 reported microRNA
expression profiles that distinguished normal tissue from
FIGURE 3. Kaplan–Meier survival curve of patients based on T stage.
FIGURE 4. Kaplan–Meier survival curve of patients based on lymph node
involvement.rgery c April 2009
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ported an association with pathologic response to neoadju-
vant chemoradiation and unique gene expression profiles.
All of these reports have demonstrated the potential utility
of gene expression profiling in esophageal adenocarcinoma.
However, none has attempted to correlate gene expression
with survival in adenocarcinoma.
We performed gene expression profiling using the DASL
assay of 502 genes that are known to be involved in carcino-
genesis. Unlike the widely reported DNA microarrays, this
assay identifies differences in gene expression of genes
whose pathways and roles in carcinogenesis are relatively
well defined. The other major advantage of this technology
is the ability to perform analysis on archived FFPE speci-
mens. DNA microarrays, although useful, typically require
a large amount of fresh or frozen tissue for analysis. Al-
though such patient tissue may be readily available at insti-
tutions that have made efforts to store the tissue, it is usually
difficult to obtain meaningful long-term clinical data owing
to the short duration of storage. In addition, some of this
tissue is collected from patients who have undergone preop-
erative chemotherapy and/or radiation therapy, thus poten-
tially altering the genetic profile of the cancer. However,
there is a vast supply of FFPE tissue from patients whose
clinical outcome is known due to the duration of storage
of FFPE at most institutions. Tissue from biopsy specimens
performed before any therapy and stored as FFPE also pres-
ent the opportunity to study tumor characteristics without the
potentially confounding variable of neoadjuvant therapy.
The ability to perform gene expression profiling using
FFPE greatly facilitates retrospective studies that can corre-
late gene expression with tumor histologic type as well as
clinical outcome. This enables the analysis of specimens
whose clinical outcome is known, that is, specimens from
patients who have follow-up of several years’ duration. In
addition, analysis of normal tissue is unnecessary, inasmuch
as all genes in the DASL array would be expected to be dif-
ferentially expressed compared with normal tissue.
Combined with bioinformatics tools, we compared differ-
ential gene expression of pathologically staged T1 and T2
esophageal adenocarcinomas versus those staged as T3
and T4 in an attempt to identify genes that may correlate
with depth of invasion. We identified a total of 63 genes
that were overexpressed in the T3-4 tumors; 21 of these
genes had a false discovery rate of 0, indicating a high likeli-
hood of significance in progression of depth of invasion.
These genes include the N-myc proto-oncogene, a gene
involved in apoptosis (LTA), a gene that belongs in the epi-
dermal growth factor family (ERBB4), as well as other onco-
genes. For the determination of genes that may be involved
in lymph node involvement, our analysis showed that the
underexpression of 1 gene, MYB, had a false discovery
rate of 0, whereas the overexpression of 16 other genes
had higher false discovery rates. The MYB gene has beenThe Journal of Thoracic and Creported to play a critical role in the differentiation/prolifer-
ation of hematopoeitic as well as other cell types and to have
latent transforming activity.17 This gene has also been re-
ported to be involved in progression of colon cancer.18
The gene expression profile of increasing T stage and that
of Nþ were noted to have some common genes (ERBB4,
ETV1, TNFSF6, MPL), suggesting that such genes have
the potential to identify tumors of advancing stage. The
gene expression profiles were correlated with overall sur-
vival and showed that underexpression of 9 genes conferred
a survival advantage. Our analysis further indicated that
gene expression was superior to T stage as well as lymph
node involvement in predicting overall survival, for the sur-
vival curves of patients with T1-2 versus T3-4 tumors as
well of patients with N0 versus Nþ tumors did not demon-
strate a statistically significant difference in survival. Some
of these genes have been correlated with survival in other
types of cancers. The SPP1 (osteopontin) gene has been re-
ported to be a determinant of decreased survival in gastric
cancer.19 The CSPG2 gene is reported to be a target for
TP53 while increased expression of IGFBP3 (insulin-like
growth factor binding protein 3) has been reported to be in-
volved in esophageal tumor growth.20,21 The heretofore
mentionedMYB gene is also involved in tumor progression.
Thus, underexpression of such genes makes intuitive sense
in terms of conferring a survival advantage.
There are several limitations to our study. We did not use
a strategy to have training and validation data sets. Although
this would be highly desirable, doing so would have led to an
even smaller number of samples in each category, thus rais-
ing questions about the statistical validity of our findings.
We used an arbitrary cutoff of 70% tumor in the selection
of our specimens. It is possible that the inclusion of normal
tissue in our analysis may have led to inclusion of normal tis-
sue gene expression. In theory, microdissection, for exam-
ple, laser capture, may lead to the extraction of more pure
tumor RNA and, perhaps, lead to a more accurate reflection
of tumor gene expression. However, most of the specimens
analyzed contained greater than 70% tumor tissue and, for
those specimens that had close to the 70% cutoff, macrodis-
section was performed in an attempt to reduce the amount of
normal tissue as much as possible. It may be more appropri-
ate to perform comparison of T1 versus T2, T2 versus T3,
and so on, to obtain a more accurate reflection of the profile
of increasing depth of invasion. However, we did not have
sufficient numbers of tumors for each T state to perform
a meaningful analysis. Inasmuch as the majority of tumors
in our analysis were T3, we believed that comparison of tu-
mors that have partially invaded the esophageal wall, that is,
T1 and T2, with those that have fully penetrated the esoph-
ageal wall would be an accurate reflection of increasing
depth of invasion. It is also possible that patients with an in-
creasing number of involved lymph nodes have differential
gene expression. Again, however, such an analysis was notardiovascular Surgery c Volume 137, Number 4 833
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did not reveal a statistically significant difference in survival
with advancing T stage or with positive lymph node involve-
ment. With regard to T stage, our combination of T1 and T2
tumors and of T3 and T4 tumors may obviously have influ-
enced such a result. However, it is also now apparent that
correlation of survival with T stage alone is imprecise, for
within each T stage (particularly early T stage) subcategories
exist that may better determine survival. It would be ideal to
perform survival analysis based on T1 versus T2 versus T3
versus T4; however, the numbers involved are too small for
a statistically valid analysis of this sort. Similarly, although
the Nþversus N0 survival analysis trended toward statistical
significance, we did not observe a significant difference in
survival in patients with Nþversus N0 tumors. This obser-
vation may be due to the fact that T stage was not considered
in this analysis. Furthermore, the number of lymph nodes
involved was also not considered; this has been shown to
influence outcomes as well.
In summary, we have performed gene expression profil-
ing of esophageal adenocarcinomas using a technique that
uses FFPE tissue and have shown correlation between a lim-
ited number of genes and increasing depth of invasion,
lymph node involvement, and overall survival. The genes
may be involved in esophageal adenocarcinoma carcinogen-
esis and may serve as potential markers of disease progres-
sion and/or prognosis. These genes may also be involved
with other genes, not yet discovered, in pathways that are
critical to carcinogenesis. Such genes may serve as potential
targets for future therapy, as markers of disease recurrence,
or as further aids in the refinement of esophageal cancer stag-
ing. Further validation of these data in a prospective manner
is needed to determine the utility of these profiles and of the
genes identified.
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